4-(1-Bromoethyl)-1,2-diethylbenzene | 119436-18-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(1-Bromoethyl)-1,2-diethylbenzene
• CAS: 119436-18-9
• 化学式: C₁₂H₁₇Br
• 分子量: 241.171
• InChiKey: NRMWINNIABMSAS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  4-(1-Bromoethyl)-1,2-diethylbenzene 在 sodium hydroxide 作用下， 以 乙醇 、 苯 为溶剂， 反应 50.0h， 生成 (E)-4-[2-(3,4-Diethylphenyl)-1-propenyl]benzoic acid
  参考文献：
  名称：

  Retinobenzoic acids. 3. Structure-activity relationships of retinoidal azobenzene-4-carboxylic acids and stilbene-4-carboxylic acids

  摘要：

  Alkyl-substituted azobenzene-4-carboxylic acids are potent differentiation inducers of human promyelocytic leukemia cell line HL-60 to mature granulocytes. Their structure-activity relationships are very similar to those of other retinoidal benzoic acids which are generally represented by 4 and named retinobenzoic acids. The structure-activity relationships of azobenzenecarboxylic acids can also be applied to the known retinoid TTNPB (3). Thus, (E)-4-[2-(3,4-diisopropylphenyl)-1-propenyl]benzoic acid (St30 (28] and (E)-4-[2-(3-tert-butylphenyl)ethenyl]benzoic acid (St40 (29], the acyclic alkyl analogues of TTNPB, are nearly as active as retinoic acid. Among the oxidatively derived compounds (Az90, Ep series and Ox series) of azobenzene- or stilbenecarboxylic acids, Az90 (71) and Ep80 (61) have strong activities. However, all the bishydroxylated derivatives of TTNPB are inactive, while a diketo analogue Ox580 (69) has only weak potency. The activities of conformationally restricted compounds of TTNPB offer some information on the stereochemistry of the active form of these retinoidal compounds.

  DOI：

  10.1021/jm00125a027
• 作为产物：
  描述：

  邻二乙苯 在 吡啶 、 sodium tetrahydroborate 、 三氯化铝 、 三溴化磷 作用下， 以 甲醇 、 乙醚 、 正己烷 、 1,2-二氯乙烷 为溶剂， 反应 4.0h， 生成 4-(1-Bromoethyl)-1,2-diethylbenzene
  参考文献：
  名称：

  Retinobenzoic acids. 3. Structure-activity relationships of retinoidal azobenzene-4-carboxylic acids and stilbene-4-carboxylic acids

  摘要：

  Alkyl-substituted azobenzene-4-carboxylic acids are potent differentiation inducers of human promyelocytic leukemia cell line HL-60 to mature granulocytes. Their structure-activity relationships are very similar to those of other retinoidal benzoic acids which are generally represented by 4 and named retinobenzoic acids. The structure-activity relationships of azobenzenecarboxylic acids can also be applied to the known retinoid TTNPB (3). Thus, (E)-4-[2-(3,4-diisopropylphenyl)-1-propenyl]benzoic acid (St30 (28] and (E)-4-[2-(3-tert-butylphenyl)ethenyl]benzoic acid (St40 (29], the acyclic alkyl analogues of TTNPB, are nearly as active as retinoic acid. Among the oxidatively derived compounds (Az90, Ep series and Ox series) of azobenzene- or stilbenecarboxylic acids, Az90 (71) and Ep80 (61) have strong activities. However, all the bishydroxylated derivatives of TTNPB are inactive, while a diketo analogue Ox580 (69) has only weak potency. The activities of conformationally restricted compounds of TTNPB offer some information on the stereochemistry of the active form of these retinoidal compounds.

  DOI：

  10.1021/jm00125a027

文献信息

• SHUDO, KOICHI
  作者：SHUDO, KOICHI

  DOI：——

  日期：——
• 1-PHENYLALKYL-1,2,3,6-TETRAHYDROPYRIDINES POUR LE TRAITEMENT DE LA MALADIE D'ALZHEIMER
  申请人：Sanofi-Synthélabo

  公开号：EP0950048A1

  公开（公告）日：1999-10-20
• UTILISATION DE DERIVES DE LA TETRAHYDROPYRIDINE POUR LA PREPARATION DE MEDICAMENTS POUR LE TRAITEMENT DES MALADIES ENTRAINANT UNE DEMYELINISATION
  申请人：SANOFI-SYNTHELABO

  公开号：EP0979079A1

  公开（公告）日：2000-02-16
• UTILISATION DE TETRAHYDROPYRIDINES 4-SUBSTITUEES POUR FABRIQUER DES MEDICAMENTS AGISSANT SUR LE TGF-BETA1
  申请人：Sanofi-Synthélabo

  公开号：EP1017385A1

  公开（公告）日：2000-07-12
• [EN] 1-PHENYLALKYL-1,2,3,6-TETRAHYDROPYRIDINES FOR TREATING ALZHEIMER'S DISEASE<br/>[FR] 1-PHENYLALKYL-1,2,3,6-TETRAHYDROPYRIDINES POUR LE TRAITEMENT DE LA MALADIE D'ALZHEIMER
  申请人：SANOFI

  公开号：WO1998025903A1

  公开（公告）日：1998-06-18

  (EN) The invention concerns compounds of formula (I) in which Y represents -CH- or -N-; R1 represents hydrogen, a halogen, a CF3 group, (C1-C4)alkyl or (C1-C4)alcoxyl; R2 represents a methyl or ethyl group; R3 and R4 each represent hydrogen or a (C1-C3)alkyl; X represents (a) a (C1-C6)alkyl; a (C1-C6)alcoxyl; a (C3-C7)carboxyalkyl; a (C1-C4)alcoxycarbonyl(C1-C6)alkyl; a (C3-C7)carboxyalcoxyl; or a (C1-C4)alcoxycarbonyl(C1-C6)alcoxyl; (b) a radical selected among a (C3-C7)cycloalkyl, (C3-C7)cycloalkyloxy, (C3-C7)cycloalkylmethyl, (C3-C7)cycloalkylamino and cyclohexenyl, said radical can be substituted by a halogen, hydroxy, (C1-C4)alcoxy, carboxy, (C1-C4)alcoxycarbonyl, amino, mono- or di-(C1-C4) alkylamino; or (c) a group selected among a phenyl, phenoxy, phenylamino, N-(C1-C3)alkylphenylamino, phenylmethyl, phenylethyl, phenylcarbonyl, phenylthio, phenylsuphonyl, phenylsulphinyl or styryl, said group can be mono- or poly-substituted by a halogen, CF3, (C1-C4)alkyl, (C1-C4)alcoxy, cyano, amino, mono- or di-(C1-C4)alkylamino, (C1-C4)acylamino, carboxy, (C1-C4)alcoxycarbonyl, aminocarbonyl, mono- or di-(C1-C4)alkylaminocarbonyl, amino(C1-C4)alkyl, hydroxy(C1-C4)alkyl or halogeno(C1-C4)alkyl. The invention also concerns a method for preparing them and the pharmaceutical compositions containing them. These compounds have a neurotrophic and neuroprotecting activity.(FR) L'invention concerne des composés de formule (I) dans laquelle Y représente -CH- ou -N-; R1 représente l'hydrogène, un halogène, un groupe CF3, (C1-C4)alkyle ou (C1-C4)alcoxyle; R2 représente un groupe méthyle ou éthyle; R3 et R4 représentent chacun l'hydrogène ou un (C1-C3)alkyle; X représente (a) un (C1-C6)alkyle; un (C1-C6)alcoxyle; un (C3-C7)carboxyalkyle; un (C1-C4)alcoxycarbonyl(C1-C6)alkyle; un (C3-C7)carboxyalcoxyle; ou un (C1-C4)alcoxycarbonyl(C1-C6)alcoxyle; (b) un radical choisi parmi un (C3-C7)cycloalkyle, (C3-C7)cycloalkyloxy, (C3-C7)cycloalkylméthyle, (C3-C7)cycloalkylamino et cyclohexényle, ledit radical pouvant être substitué par un halogène, hydroxy, (C1-C4)alcoxy, carboxy, (C1-C4)alcoxycarbonyle, amino, mono- ou di-(C1-C4)alkylamino; ou (c) un groupe choisi parmi un phényle, phénoxy, phénylamino, N-(C1-C3)alkylphénylamino, phénylméthyle, phényléthyle, phénylcarbonyle, phénylthio, phénylsulfonyle, phénylsulfinyle ou styryle, ledit groupe pouvant être mono- ou polysubstitué sur le groupe phényle par un halogène, CF3, (C1-C4)alkyle, (C1-C4)alcoxy, cyano, amino, mono- ou di-(C1-C4)alkylamino, (C1-C4)acylamino, carboxy, (C1-C4)alcoxycarbonyle, aminocarbonyle, mono- ou di-(C1-C4)alkylaminocarbonyle, amino(C1-C4)alkyle, hydroxy(C1-C4)alkyle ou halogéno(C1-C4)alkyle; ainsi qu'un procédé pour leur préparation et les compositions pharmaceutiques les contenant. Ces composés ont une activité neurotrophique et neuroprotectrice.